

PEER REVIEW HISTORY

BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (<http://bmjopen.bmj.com/site/about/resources/checklist.pdf>) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.

ARTICLE DETAILS

TITLE (PROVISIONAL)	Diagnostic Accuracy of Imaging Brain Vesicular Monoamine Transporter type-2 (VMAT2) in Clinically Uncertain Parkinsonian Syndrome (CUPS): a 3 year follow-up study in community patients.
AUTHORS	Xu, San San; Alexander, Paschal; Lie, Yenni; Dore, Vincent; Bozinovski, Svetlana; Mulligan, Rachel; Young, Kenneth; Villemagne, Victor; Rowe, Christopher C.

VERSION 1 – REVIEW

REVIEWER	Ralph Buchert Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
REVIEW RETURNED	07-Aug-2018

GENERAL COMMENTS	I would like to thank the authors for their thoughtful revision. I'm fully satisfied with the response to my (and the other reviewer's) comments and suggestions as well as with the corresponding changes in the manuscript. I have only one very minor comment concerning the "Strengths and Limitations" section added after the abstract: what is meant by "The 18F-AV-133 PET offers advantages compared to DaTSCAN including ... more precise quantitation and reduced tracer uptake..."?
-------------------------	---

VERSION 1 – AUTHOR RESPONSE

In regard to the the editor's comments: the Title, Abstract and "Strength and Limitations" section has been updated as illustrated in the manuscript (mark up) attached.

In regard to the reviewer's comments: The statement "The 18F-AV-133 PET offers advantages compared to DatSCAN including...more precise quantitation and reduced tracer uptake..." has since been removed from the "Strengths and limitations", so that only sentences relating to the method have been included. There is a similar statement in the discussion, which has been revised to "There are advantages of 18F-AV-133 PET including improved spatial resolution and there is reduced tracer uptake and scan acquisition time in comparison to DaTSCAN, without the need for thyroid blockade or other patient preparation".